Randomized, Placebo-Controlled Trial of Rifaximin Therapy for Lowering Gut-Derived Cardiovascular Toxins and Inflammation in CKD is a research paper published in Kidney360 (2020). On theSindex it has a DataRank of 0.817. It has been cited 22 times, with 22 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.470
From this paper's citation signal
Citation Network Contribution
0.347
From 15 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 22 citers.
National Institute of Diabetes and Digestive and Kidney Diseases
Grant: R21DK108093
National Center for Advancing Translational Sciences
Grant: UL1TR000001
NIDDK NIH HHS
Grant: P30 DK035816
NIGMS NIH HHS
Grant: P20 GM130423
National Institutes of Health
University of Colorado GI and Liver Innate Immune Program
MeSH Terms